Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03842137 · ClinicalTrials.gov registry record · NA
tDCS to Decrease Opioid Relapse (UG3)
A NA study, sponsored by Butler Hospital.
- Completed
- Registry status
- NA
- Development phase
- 62
- Enrollment target
NCT03842137 is a NA study that has completed, run by Butler Hospital. The registered enrollment target is 62 participants.
The verdict
NCT03842137, a NA study, has completed, sponsored by Butler Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 62 participants
- Enrollment target
Study Summary
In the current proposal, the investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. Participants with opioid dependence, in the first month of prescribed buprenorphine or methadone, will be assessed twice using electroencephalographic (EEG), once prior to tDCS+CCN priming and again at the completion of 5 sessions of tDCS+CCN priming (one week later). EEG will provide validation of expected changes in these networks following tDCS stimulation of the DLPFC.
Interventions
- DEVICE sham tDCS
- DEVICE tDCS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2019-06-04 |
| Est. Completion | 2023-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03842137
The ClinicalTrials.gov registry entry for NCT03842137 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Butler Hospital, which has 103 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sham tDCS is the first listed.
NCT03842137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03842137 about?
NCT03842137 is a clinical study titled "tDCS to Decrease Opioid Relapse (UG3)". In the current proposal, the investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. Pa...
What is the current status of trial NCT03842137?
This trial is currently completed. It is a NA study. The enrollment target is 62 participants. The study started on 2019-06-04. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT03842137?
The interventions under investigation include: sham tDCS (DEVICE), tDCS (DEVICE).
Who is sponsoring clinical trial NCT03842137?
This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.